A Two-Cohort Randomized Phase 2 Trial of the IRX-2 Regimen in Women With Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3)
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2018
At a glance
- Drugs IRX 2 (Primary) ; IRX 2 (Primary) ; Cyclophosphamide; Indometacin; Omeprazole
- Indications Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Feb 2018 According to an IRX Therapeutics media realease, first patient has been dosed in this trial.
- 15 Nov 2017 Planned End Date changed from 30 Oct 2022 to 8 Nov 2022.